Chamot A M, Gerster J C, Van Melle G
Service de rhumatologie, Médecine physique et Réhabilitation, CHUV, Lausanne.
Schweiz Med Wochenschr. 1988 Sep 10;118(36):1267-71.
28 patients with severe rheumatoid arthritis were treated with pulse weekly oral methotrexate over a mean follow-up of 24 months (6-36 months). Within one month the patients improved significantly by all clinical standards of efficacy and erythrocyte sedimentation rate. Maximum improvement tended to occur after 6 months' therapy and was maintained for up to 36 months in most patients. 11 patients discontinued treatment because of adverse effects. It is concluded that this trial confirms the efficacy of methotrexate in rheumatoid arthritis. Careful baseline and follow-up monitoring is recommended due to frequent adverse reactions.
28例重症类风湿关节炎患者接受每周一次口服甲氨蝶呤冲击治疗，平均随访24个月（6 - 36个月）。在一个月内，按照所有临床疗效标准和红细胞沉降率，患者病情显著改善。最大改善往往在治疗6个月后出现，大多数患者在长达36个月的时间内病情得到维持。11例患者因不良反应而停止治疗。得出的结论是，该试验证实了甲氨蝶呤对类风湿关节炎的疗效。由于不良反应频繁，建议进行仔细的基线和随访监测。
